Myogem’s MyoDM clinical study successfully completes patient recruitment. Post on LinkedIn.

At the end of February 2021, the patient recruitment phase of the clinical study NCT04634682 by Myogem concluded. The study evaluates the effect of the MYO-DM food supplement on quality of life, fatigue, neuromuscular and physical capacity, and hypersomnia in patients with DM1.

LinkedIn post

MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.
Buy now

¿Do you have any questions
or need more information?

Fill out the form and our team will respond as soon as possible.
Email *
Subject *
Message *

Related news.

Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.

View report
Ver más

Doctoral thesis

Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****
Ver más

Scientific article compiling the most recent drug development projects currently in the preclinical and clinical phases

View report
Ver más